Cargando…
Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions
Plazomicin is a recent U.S. Food and Drug Administration (FDA)-approved semisynthetic aminoglycoside. Its structure consists of a sisomicin scaffold modified by adding a 2(S)-hydroxy aminobutyryl group at the N1 position and a hydroxyethyl substituent at the 6′ position. These substitutions produced...
Autores principales: | Ngo, David, Magaña, Angel J., Tran, Tung, Sklenicka, Jan, Phan, Kimberly, Eykholt, Brian, Jimenez, Verónica, Ramirez, María S., Tolmasky, Marcelo E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966628/ https://www.ncbi.nlm.nih.gov/pubmed/37259383 http://dx.doi.org/10.3390/ph16020236 |
Ejemplares similares
-
Aminoglycoside 6′-N-acetyltransferase Type Ib [AAC(6′)-Ib]-Mediated Aminoglycoside Resistance: Phenotypic Conversion to Susceptibility by Silver Ions
por: Reeves, Craig M., et al.
Publicado: (2020) -
Structural basis for plazomicin antibiotic action and resistance
por: Golkar, Tolou, et al.
Publicado: (2021) -
Restoration of susceptibility to amikacin by 8-hydroxyquinoline analogs complexed to zinc
por: Magallon, Jesus, et al.
Publicado: (2019) -
Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae
por: Serio, Alisa W, et al.
Publicado: (2019) -
Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance
por: Clark, Justin A., et al.
Publicado: (2020)